Extracorporeal photopheresis: a focus on apoptosis and cytokines
- PMID: 16797926
- DOI: 10.1016/j.jdermsci.2006.05.004
Extracorporeal photopheresis: a focus on apoptosis and cytokines
Abstract
Induction of apoptosis and changes to cytokine secretion patterns have been implicated in the mechanism of action of extracorporeal photopheresis (ECP). Lymphocyte apoptosis is initially detected in significant numbers prior to re-infusion and by 48 h post-ECP the majority of treated lymphocytes are apoptotic. The early apoptosis involves changes to mitochondrial function, reversal of the Bcl-2/Bax ratio and externalisation of phosphatidylserine. Apoptotic lymphocytes, observed from 20 h post-ECP, are associated with enhanced levels of CD95 and Fas-ligand. For cutaneous T cell lymphoma (CTCL), processing of the apoptotic lymphocytes, by suitable antigen presenting cells (APCs), is suggested to induce a clonal cytotoxic response which targets the malignant T cell population. Increased levels of TNFalpha and IFNgamma, observed post-ECP in monocytes and lymphocytes, respectively, are thought to further contribute to the proposed anti-tumour reaction seen in CTCL. However, down-regulation of pro-inflammatory cytokines and enhanced anti-inflammatory responses have been reported following ECP treatment. These immune responses may contribute to the tempering of the inflammatory conditions, such as graft versus host disease, which respond to ECP. Furthermore, untreated monocytes exposed to ECP-treated lymphocytes have also demonstrated a shift in monocyte cytokine-secretory pattern, toward one associated with immune tolerance. Recently, a mechanism of ECP-induced immune tolerance has been linked to the stimulation of the anti-inflammatory cytokines IL10 and TGFbeta by T regulatory cells, following the infusion of ECP-treated CD11c(+) APCs. Ultimately, the multifaceted responses, induced by ECP, may explain the diversity of clinical conditions that benefit.
Similar articles
-
Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.J Clin Apher. 2002;17(4):177-82. doi: 10.1002/jca.10039. J Clin Apher. 2002. PMID: 12494410
-
The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phosphatidylserine externalization.Transpl Int. 2006 Apr;19(4):319-24. doi: 10.1111/j.1432-2277.2006.00278.x. Transpl Int. 2006. PMID: 16573548
-
Lymphocytes treated by extracorporeal photopheresis can down-regulate cytokine production in untreated monocytes.Photodermatol Photoimmunol Photomed. 2005 Dec;21(6):293-302. doi: 10.1111/j.1600-0781.2005.00192.x. Photodermatol Photoimmunol Photomed. 2005. PMID: 16313240
-
Mechanisms of action of extracorporeal photochemotherapy.Transfus Apher Sci. 2003 Aug;29(1):61-70. doi: 10.1016/S1473-0502(03)00103-4. Transfus Apher Sci. 2003. PMID: 12877896 Review.
-
Extracorporeal photopheresis: from solid organs to face transplantation.Transpl Immunol. 2009 Jul;21(3):117-28. doi: 10.1016/j.trim.2009.04.005. Epub 2009 May 3. Transpl Immunol. 2009. PMID: 19409991 Review.
Cited by
-
Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.Am J Hematol. 2021 Oct 1;96(10):1313-1328. doi: 10.1002/ajh.26299. Epub 2021 Aug 2. Am J Hematol. 2021. PMID: 34297414 Free PMC article.
-
Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease.Pharmaceuticals (Basel). 2024 Sep 27;17(10):1279. doi: 10.3390/ph17101279. Pharmaceuticals (Basel). 2024. PMID: 39458920 Free PMC article.
-
Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience.Biol Blood Marrow Transplant. 2015 Nov;21(11):1963-72. doi: 10.1016/j.bbmt.2015.07.007. Epub 2015 Jul 14. Biol Blood Marrow Transplant. 2015. PMID: 26183078 Free PMC article.
-
Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma.Leukemia. 2025 Feb;39(2):438-450. doi: 10.1038/s41375-024-02479-1. Epub 2024 Nov 23. Leukemia. 2025. PMID: 39580583 Free PMC article.
-
Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.Cells. 2021 Apr 23;10(5):987. doi: 10.3390/cells10050987. Cells. 2021. PMID: 33922439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous